Evidence map›Paper›PMID 41834838›Full record

ReviewFrontiers in allergy2026

Advance in biologics for chronic rhinosinusitis with nasal polyps.

Yiming Di, Ruizhi Zeng, Lei Huang, Yong Wu, Qingwu Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Past, the Present, and the Future of Periostin in Allergy.Allergy, asthma & immunology research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yiming Di *Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ruizhi Zeng *Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Lei Huang *Department of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yong Wu *Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Qingwu WuDepartment of Otorhinolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Managing chronic rhinosinusitis with nasal polyps (CRSwNP) poses challenges, especially when conventional treatments fail to achieve adequate symptom control. CRSwNP is often marked by type 2 inflammation, and a large number of patients have other comorbid type 2 conditions, such as asthma. Currently, 4 biologics have been approved to treat CRSwNP-dupilumab, omalizumab, mepolizumab, and stapokibart (stapokibart is approved in China but not by the US Food and Drug Administration)-with additional promising therapies currently under development. Biologics can enhance the quality of life for CRSwNP patients, reduce the need for systemic corticosteroid therapy and endoscopic sinus surgery (ESS), and improve the management of comorbid conditions. We review clinical trials and real-world data on the effectiveness and safety of biologics for CRSwNP, compare biologic therapy and ESS, and explore the switching and simultaneous use of biologics.

Indexed as

biologicschronic rhinosinusitis with nasal polypsdrug switchingefficacyendoscopic sinus surgerysafetytype 2 inflammation

Identifiers

PMID41834838
PMCPMC12982369

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.